Ken Griffin Cardiol Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 37,600 shares of CRDL stock, worth $42,487. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,600
Previous 25,900
45.17%
Holding current value
$42,487
Previous $25,000
104.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CRDL
# of Institutions
43Shares Held
6.74MCall Options Held
37.6KPut Options Held
0-
Tejara Capital LTD London, X03.27MShares$3.69 Million2.06% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD857KShares$968,8480.22% of portfolio
-
Pvg Asset Management Corp Golden, CO437KShares$494,2191.99% of portfolio
-
Lion Street Advisors, LLC340KShares$384,2280.15% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9293KShares$331,1530.15% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $70M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...